The linked resource below is bookmarked on the Internet.  Please click the "Visit Resource" button below to read the full story.

"An arbitration panel, on June 16, 2009, reaffirmed Biogen's contractual right to fully participate in strategic decisions regarding the development of Rituxan or rituximab and other anti-CD20 antibodies with Genentech, Inc. The arbitration panel rejected Genentech's assertion that the November 2003 merger of IDEC Pharmaceuticals Corp. and Biogen Inc. constituted a change of control. Idec co-promotes Rituxan that is indicated in certain B-cell non-Hodgkin's lymphomas and rheumatoid arthritis, with Genentech in the United States. The arbitration panel also ruled that a Joint Development Committee comprised of three members from each company must unanimously approve a development plan for each specific indication. The panel also indicated that Genentech may not proceed with further development of 2H7v16 in neuromyelitis optica, 2H7v16 in relapsing-remitting multiple sclerosis, or 2H7v114 for oncology in case of unanimous decision.An n arbitration panel, reaffirming its contractual right to fully participate in strategic decisions regarding the development of Rituxan or rituximab and other anti-CD20 antibodies with Genentech, Inc. The arbitration panel also ruled that a Joint Development Committee comprised of three members from each company must unanimously approve a development plan for each specific indication. The panel indicated thatwithout such unanimous approval, Genentech may not proceed with further development of 2H7v16 in neuromyelitis optica."